Abstract
6 min read<h3>Objective:</h3> We investigated the impact of Single Nucleotide Polymorphisms (SNPs) in genes implicated in iron metabolism on the risk of developing progressive MS. <h3>Background:</h3> Iron enrichment is a core feature of chronic active lesions, a key marker of progressive MS, and can be detected by magnetic resonance imaging. In parallel, the molecular profile of the lesion-associated microglia supports the relevance of genes involved in iron metabolism. However, it is still unclear their role in disease progression. <h3>Design/Methods:</h3> We performed an association analysis on 37,794 SNPs in 319 genes involved in iron metabolism, comparing benign relapsing-remitting (RR) versus secondary progressive (SP) patients in a discovery Italian cohort from San Raffaele Hospital (OSR). Significant results were investigated in a nationwide replication cohort from Sweden (SWE). Benign RR-MS was defined as a confirmed RR course of at least 20 years and EDSS<=3.5. In the SP group, patients with confirmed conversion to SP within 20 years from onset and EDSS=>4.0 were included. <h3>Results:</h3> After quality controls, 2,817 patients were studied. We found a significant association involving SNPs in the Hypoxia-Inducible-Factor-1-alfa (<i>HIF1A</i>) gene in the discovery cohort (n=755; lead-SNP=rs11621525; p=3.30E-06, OR_SP=0.57), that was replicated in the SWE cohort (n=2,062; lead-SNP=rs1951795; p=0.0079, OR_SP=0.79). Previous evidence has shown that rs11621525_A down-regulates <i>HIF1A</i> expression in whole blood in healthy subjects. We replicated this effect in peripheral blood mononuclear cells from 78 RR-MS patients (p=0.034). We also studied the neurofilament (NFL) levels, a recognized marker of ongoing axonal injury and chronic white matter inflammation. RR-MS patients who were carriers of the A allele showed lower NFL, both in plasma (n=117; p=0.0026) and in cerebrospinal fluid (n=77; p=0.051). <h3>Conclusions:</h3> Genetic variants in <i>HIF1A</i> are associated with risk of progressive MS course and impact NFL levels. HIF1A is a fundamental regulator of iron metabolism, response to hypoxia and immune processes, therefore representing a promising candidate for further investigation. <b>Disclosure:</b> Mr. Giordano has nothing to disclose. Silvia Santoro has nothing to disclose. Melissa Sorosina has nothing to disclose. Elisabetta Mascia, 3236 has nothing to disclose. Ferdinando Clarelli, 3239 has nothing to disclose. Miryam Cannizzaro has nothing to disclose. Laura Ferrè, 3233 has received intellectual property interests from a discovery or technology relating to health care. Dr. Moridi has received research support from EU Horizon 2020. Dr. Moridi has received research support from Karolinska Institutet. Dr. Stridh has nothing to disclose. Dr. Shchetynsky has nothing to disclose. Dr. Needhamsen has nothing to disclose. Dr. Piehl has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Parexel/Chugai. The institution of Dr. Piehl has received research support from UCB. The institution of Dr. Piehl has received research support from Merck KGaA. Dr. Piehl has received personal compensation in the range of $10,000-$49,999 for serving as a member scientific advisory board with Swedish Medical products Agency. The institution of Lars Alfredsson, 7582 has received research support from AFA insurance . The institution of Lars Alfredsson, 7582 has received research support from Swedish Research Council. The institution of Lars Alfredsson, 7582 has received research support from Swedish Brain Foundation. The institution of Lars Alfredsson, 7582 has received research support from Region Stockholm. Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Celgene. Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sandoz. Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. The institution of Dr. Hillert has received research support from Biogen. The institution of Dr. Hillert has received research support from Celgene. The institution of Dr. Hillert has received research support from Merck. The institution of Dr. Hillert has received research support from Novartis. The institution of Dr. Hillert has received research support from Sanofi. The institution of Dr. Hillert has received research support from Roche. Prof. Olsson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Prof. Olsson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Prof. Olsson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Prof. Olsson has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. The institution of Prof. Olsson has received research support from Biogen. The institution of Prof. Olsson has received research support from Novartis. The institution of Prof. Olsson has received research support from Sanofi. The institution of Prof. Olsson has received research support from Merck. The institution of Ingrid Kockum has received research support from Swedish Research council. The institution of Ingrid Kockum has received research support from National MS society. The institution of Ingrid Kockum has received research support from EU Horizon 2020. The institution of Prof. Jagodic has received research support from Swedish Research Council. The institution of Prof. Jagodic has received research support from EU Horizon 2020 (MultipleMS). The institution of Prof. Jagodic has received research support from European Research Council (ERC-CoG). Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries. Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries. Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA). Federica Esposito has received personal compensation in the range of $0-$499 for serving as a Consultant for Merck. Federica Esposito has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Federica Esposito has received personal compensation in the range of $0-$499 for serving as a Consultant for Novartis. Federica Esposito has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Federica Esposito has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. The institution of Federica Esposito has received research support from Italian MS Society. The institution of Federica Esposito has received research support from Italian Ministry of Health. The institution of Federica Esposito has received research support from ERA Net. The institution of Federica Esposito has received research support from European Commission. Federica Esposito has received intellectual property interests from a discovery or technology relating to health care.
Discussion(0)
No comments yet. Be the first to comment.